These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16623654)

  • 21. Exercise responses in boys with attention deficit/hyperactivity disorder: effects of stimulant medication.
    Mahon AD; Stephens BR; Cole AS
    J Atten Disord; 2008 Sep; 12(2):170-6. PubMed ID: 17998414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does stimulant treatment lead to substance use disorders?
    Faraone SV; Wilens T
    J Clin Psychiatry; 2003; 64 Suppl 11():9-13. PubMed ID: 14529324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Childhood stimulant treatment and risk for later substance abuse.
    Fischer M; Barkley RA
    J Clin Psychiatry; 2003; 64 Suppl 11():19-23. PubMed ID: 14529326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attention-deficit/hyperactivity disorder: are we medicating for social disadvantage? (For).
    Isaacs D
    J Paediatr Child Health; 2006 Sep; 42(9):544-7. PubMed ID: 16925542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder?
    Waschbusch DA; Pelham WE; Waxmonsky J; Johnston C
    J Dev Behav Pediatr; 2009 Apr; 30(2):158-68. PubMed ID: 19363369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder--United States, 2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(34):842-7. PubMed ID: 16138075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants.
    Roessner V; Robatzek M; Knapp G; Banaschewski T; Rothenberger A
    Dev Med Child Neurol; 2006 Jul; 48(7):616-21. PubMed ID: 16780635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG; Perrin JM; Shelley-Abrahamson R; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):978-90. PubMed ID: 21961773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrative neuroscience approach to predict ADHD stimulant response.
    Hermens DF; Rowe DL; Gordon E; Williams LM
    Expert Rev Neurother; 2006 May; 6(5):753-63. PubMed ID: 16734523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving psychostimulant adherence in children with ADHD.
    Charach A; Gajaria A
    Expert Rev Neurother; 2008 Oct; 8(10):1563-71. PubMed ID: 18928348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment.
    Leibson CL; Barbaresi WJ; Ransom J; Colligan RC; Kemner J; Weaver AL; Katusic SK
    Ambul Pediatr; 2006; 6(1):45-53. PubMed ID: 16443183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming the barriers to effective treatment for attention-deficit/hyperactivity disorder: a neuro-educational approach.
    Monastra VJ
    Int J Psychophysiol; 2005 Oct; 58(1):71-80. PubMed ID: 15927296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
    Upadhyaya HP
    J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescribed stimulant use by Western Australians with Attention Deficit Hyperactivity Disorder (ADHD): does amount dispensed exceed the expected authorised use?
    Calver J; Sanfilippo F; Preen D; Bulsara M
    Aust N Z J Public Health; 2007 Dec; 31(6):533-9. PubMed ID: 18081573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychopharmacological interventions.
    Biederman J; Spencer TJ
    Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):439-58, xi. PubMed ID: 18295155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological treatment of attention-deficit/hyperactivity disorder in adults].
    Rollini M; Baud P
    Rev Med Suisse; 2008 Jul; 4(165):1638-43. PubMed ID: 18767289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.